This thesis focusses on the challenges relating to clinical- and cost-effectiveness analysis in Health Technology Assessment (HTA). It includes methodological developments, both statistical and presentational, in evidence synthesis aiming to address those challenges. In HTA, analysts often face problems with limited availability of data required to inform economic model. This thesis proposes innovative evidence synthesis approaches to address this challenge, illustrated in two examples. Bivariate random-effects meta-analysis (BRMA) and network meta-analysis (NMA) were used to synthesise all available evidence to predict progression-free survival (PFS), in metastatic prostate cancer. This enabled the specification of a three-state Markov mod...
The evidence produced by healthcare economic evaluation studies is a key component of any Health Tec...
This paper presents a preliminary report of the Italian Society of Medical Statistics and Clinical E...
Studies of clinical efficacy commonly report more than one clinical endpoint. For example, randomize...
This thesis focusses on the challenges relating to clinical- and cost-effectiveness analysis in Heal...
This thesis explores the challenges of assessing the relative effectiveness of new health technologi...
Sequential use of alternative treatments for chronic conditions represents a complex intervention pa...
Background Evaluations of diagnostic tests are challenging because of the indirect nature of their i...
textabstractHealth technology assessment (HTA) originated from the spread of costly medical equipmen...
This thesis addresses the issue of incorporating real world data (RWD) on treatment effectiveness in...
Objectives: Health Technology Assessment (HTA) needs to address the challenges posed by high cost, e...
Objectives Health technology assessments (HTAs) typically require the development of a cost-effectiv...
In health technology assessment, decisions are based on complex cost-effectiveness models which requ...
Alongside the development of meta-analysis as a tool for summarizing research literature, there is r...
ABSTRACTObjectivesHealth technology assessments (HTAs) typically require the development of a cost-e...
This thesis considers the quantitative synthesis of evidence from different study types in order to ...
The evidence produced by healthcare economic evaluation studies is a key component of any Health Tec...
This paper presents a preliminary report of the Italian Society of Medical Statistics and Clinical E...
Studies of clinical efficacy commonly report more than one clinical endpoint. For example, randomize...
This thesis focusses on the challenges relating to clinical- and cost-effectiveness analysis in Heal...
This thesis explores the challenges of assessing the relative effectiveness of new health technologi...
Sequential use of alternative treatments for chronic conditions represents a complex intervention pa...
Background Evaluations of diagnostic tests are challenging because of the indirect nature of their i...
textabstractHealth technology assessment (HTA) originated from the spread of costly medical equipmen...
This thesis addresses the issue of incorporating real world data (RWD) on treatment effectiveness in...
Objectives: Health Technology Assessment (HTA) needs to address the challenges posed by high cost, e...
Objectives Health technology assessments (HTAs) typically require the development of a cost-effectiv...
In health technology assessment, decisions are based on complex cost-effectiveness models which requ...
Alongside the development of meta-analysis as a tool for summarizing research literature, there is r...
ABSTRACTObjectivesHealth technology assessments (HTAs) typically require the development of a cost-e...
This thesis considers the quantitative synthesis of evidence from different study types in order to ...
The evidence produced by healthcare economic evaluation studies is a key component of any Health Tec...
This paper presents a preliminary report of the Italian Society of Medical Statistics and Clinical E...
Studies of clinical efficacy commonly report more than one clinical endpoint. For example, randomize...